Canntab Therapeutics Signs Joint Venture Agreement with Queensland Bauxite Subsidiary

- January 10th, 2018

Canntab Therapeutics has recently entered into a joint venture agreement with VitaCann, a subsidiary of Medical Cannabis, which is owned by Queensland Bauxite (ASX:QBL) in Australia.

Canntab Therapeutics has recently entered into a joint venture agreement with VitaCann, a subsidiary of Medical Cannabis, which is owned by Queensland Bauxite (ASX:QBL) in Australia. The Finance News Network published a video segment regarding the news, highlighting that the companies are working towards having Canntab tablets approved for sale within the Australian market and for export to Asia.
This joint venture has positioned Canntab and its Australian partner favorably to expand production and manufacturing of the Medical Cannabis seed bank and products within the Australian market.
To watch the full video segment, click here.
Click here to connect with Canntab Therapeutics for investor information.

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

One response to “Canntab Therapeutics Signs Joint Venture Agreement with Queensland Bauxite Subsidiary

Leave a Reply

Your email address will not be published. Required fields are marked *